Table 4 Mechanistic insights into HMGB1 in heart failure and remodelling (beneficial effects)
From: Scoping review of preclinical and clinical studies on the role of HMGB1 in heart disease
Authors (Year) | Study population (Model) | Time of interventions (in vivo route) | Agonist HMGB1 (Supplier) | Antagonist HMGB1 | Receptors and Pathways |
|---|---|---|---|---|---|
Funayama et al. (2013)49 | Patients (HF); NRCMs (ET-1&Ang II); WT & HMGB1-Tg mice (TAC) | – | Cardiomyocyte-specific HMGB1 overexpression (α-MHC promoter) | siRNA | – |
Goto et al. (2020)105 | SD rats (PL) | 2wk post MI (i.v.) | HMGB1 Box-A fragment (StemRIM) | – | – |
He et al. (2013)99 | SD rats (PL) | 3wk post MI (i.m.c.) | rHMGB1 (R&D) | – | TGF-β-Smad |
Limana et al. (2011)98 | C57Bl/6mice (PL) | 3wk post MI (i.m.c.) | rHMGB1 (HMGBiotech)a | – | c-kit+ cardiac stem cells; miR-206 and inhibition of TIMP-3 |
Li et al. (2019)96 | NRCMs (ang-II, PE, ISO); SD rats (3AB, AAC) | – | HMGB1 overexpression by transfection (plasmid pcDNA3.1-6Flag-HMGB1) | – | PARP1-mediated nuclear HMGB1 translocation |
Takahashi et al. (2008)104 | SD rats (PL) | 3wk post MI (i.m.c.) | rHMGB1 (R&D) | – | ERK1/2 |
Takahashi et al. (2019)50 | Patients (HF); NRCMs (Ang II); WT & HMGB1-Tg mice (TAC) | – | Cardiomyocyte-specific HMGB1 overexpression (α-MHC promoter) | siRNA | – |
Yang et al. (2022)97 | LysM-HMGB1−/− mice (TAC) | – | – | Myeloid-specific HMGB1 deletion | TGF-β-Smad |
